Why the Cogstate (ASX:CGS) share price is surging 23% today

There are several different factors that are moving the neuroscience technology company’s share price.

| More on:
A drawing of a rocket follows a chart up, indicating share price lift

Image source: Getty Images

The Cogstate Limited (ASX: CGS) share price has bolted more than 23% in today’s trading session.

At the time of writing, shares in Cogstate are trading at around $1.48, after hitting an intra-day high of $1.49.

Let’s take a look at what could be fuelling the Cogstate share price.

What is fueling the Cogstate share price?

Despite not releasing any price-sensitive news, the Cogstate share price is bolting more than 19% higher today. Due to the lack of market moving news, today’s euphoric price action can be attributed to many factors.

The last piece of news from Cogstate can be traced back to a market update released on 15 June. According to the update, Cogstate’s wholly-owned US subsidiary received confirmation that federal loan funds had been fully forgiven.

In May 2020, Cogstate Inc secured a US$2.44 million loan under the United States Government Small Business Administration Payroll Protection Program (PPP). Cogstate noted that the PPP allowed companies to maintain their workforce as the pandemic disrupted business operations.

Snapshot of the Cogstate share price.

Cogstate is a neuroscience technology company that specialises in brain health assessments, with the aim of advancing the development of new medicines and clinical insights. The company’s technologies allow for rapid and reliable computerised cognitive tests, which are designed to replace traditional costly and error-prone paper assessments.

Including today’s price action, the Cogstate share price is flying more than 35% higher for the year. Shares in Cogstate hit an all-time high of $1.60 earlier this month following a very positive business update.  

Cogstate announced that the U.S. Food and Drug Administration (FDA) had granted Eisai Co accelerated approval for aducanumab for the treatment of Alzheimer’s disease.

Late last year, Cogstate announced that it had entered into an agreement with Eisai Co to grant the company rights to exclusively develop and distribute Cogstate technologies.

As a result, Cogstate noted that following the approval of aducanumab by the FDA, Eisai no longer has the right to accelerated termination of the Cogstate-Eisai agreement. Eisai is contractually obligated to minimum contractual royalty payments over commercial years 1-5 of US$10 million.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of January 12th 2022

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers